ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Everest Medicines Announces Taiwan, China,China FDA Has Accepted New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer
January 04, 2022Everest Medicines Limited (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products in Asia... -
First Patient Dosed in Phase 3 Registration Asian Study of Trodelvy for Breast Cancer
December 30, 2020Everest Medicines announced the first patient has been dosed in the Phase 3 registration Asian study EVER-132-002 evaluating TrodelvyTM (sacituzumab govitecan) versus treatment of physician’s choice (TPC) in subjects with hormonal ... -
Experimental Drug Helps Women With Deadly Type of Breast Cancer
February 21, 2019An experimental drug has shown promise in extending the lives of women suffering from a particularly aggressive and deadly type of breast cancer, according to the results of a phase 2 trial.... -
Immunomedics Expands Clinical Collaboration With Astrazeneca to Include Metastatic Non-Small Cell Lung Cancer
November 09, 2018Phase 2 Platform Study to Evaluate the Combination of Imfinzi® (Durvalumab) and Sacituzumab Govitecan in Patients with Non-Small Cell Lung Cancer Who Progressed -
Seattle Genetics Announces Agreement with Immunomedics for Sacituzumab Govitecan, a Promising Late-S
February 13, 2017Seattle Genetics has announced a development and license agreement with Immunomedics, Inc.
Pharma Sources Insight January 2025
